Selective serotonin reuptake inhibitors in the context of hepatitis C infection

Reexamining the risks of bleeding

Kari A. Martin, Lois Elaine Krahn, Vijayan Balan, Marianne J. Rosati

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: Selective serotonin reuptake inhibitors (SSRIs) are used to treat interferon-associated depression in patients receiving hepatitis C virus therapy. Prior studies have cautioned against the combined use of SSRIs and interferon due to increased risk of hemorrhage. Given the morbidity of depression and its impact on interferon compliance, we sought to reexamine the data. Method: In a retrospective analysis of our database of hepatitis C virus patients, a consecutive series of 303 patients (receiving treatment between January 2001 and January 2005) were evaluated for any evidence of bleeding. On the basis of our standard practice of care, patients were treated prophylactically with antidepressants for 3 to 4 weeks before beginning combination therapy with interferon and ribavirin. Patients were evaluated every 4 weeks during antiviral treatment with physical examinations and complete blood cell counts with differentials and platelets. Results: The overall rate of bleeding in our study was 0.3%, representing a single case of hemophilia. Conclusions: The bleeding risk of SSRIs is lower than previously reported.

Original languageEnglish (US)
Pages (from-to)1024-1026
Number of pages3
JournalJournal of Clinical Psychiatry
Volume68
Issue number7
StatePublished - Jul 2007

Fingerprint

Serotonin Uptake Inhibitors
Hepatitis C
Interferons
Hemorrhage
Infection
Blood Cell Count
Hepacivirus
Ribavirin
Hemophilia A
Therapeutics
Standard of Care
Antidepressive Agents
Compliance
Physical Examination
Antiviral Agents
Blood Platelets
Databases
Morbidity

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Selective serotonin reuptake inhibitors in the context of hepatitis C infection : Reexamining the risks of bleeding. / Martin, Kari A.; Krahn, Lois Elaine; Balan, Vijayan; Rosati, Marianne J.

In: Journal of Clinical Psychiatry, Vol. 68, No. 7, 07.2007, p. 1024-1026.

Research output: Contribution to journalArticle

@article{cda77944b96a4f4cab9deaa49f129b56,
title = "Selective serotonin reuptake inhibitors in the context of hepatitis C infection: Reexamining the risks of bleeding",
abstract = "Objective: Selective serotonin reuptake inhibitors (SSRIs) are used to treat interferon-associated depression in patients receiving hepatitis C virus therapy. Prior studies have cautioned against the combined use of SSRIs and interferon due to increased risk of hemorrhage. Given the morbidity of depression and its impact on interferon compliance, we sought to reexamine the data. Method: In a retrospective analysis of our database of hepatitis C virus patients, a consecutive series of 303 patients (receiving treatment between January 2001 and January 2005) were evaluated for any evidence of bleeding. On the basis of our standard practice of care, patients were treated prophylactically with antidepressants for 3 to 4 weeks before beginning combination therapy with interferon and ribavirin. Patients were evaluated every 4 weeks during antiviral treatment with physical examinations and complete blood cell counts with differentials and platelets. Results: The overall rate of bleeding in our study was 0.3{\%}, representing a single case of hemophilia. Conclusions: The bleeding risk of SSRIs is lower than previously reported.",
author = "Martin, {Kari A.} and Krahn, {Lois Elaine} and Vijayan Balan and Rosati, {Marianne J.}",
year = "2007",
month = "7",
language = "English (US)",
volume = "68",
pages = "1024--1026",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "7",

}

TY - JOUR

T1 - Selective serotonin reuptake inhibitors in the context of hepatitis C infection

T2 - Reexamining the risks of bleeding

AU - Martin, Kari A.

AU - Krahn, Lois Elaine

AU - Balan, Vijayan

AU - Rosati, Marianne J.

PY - 2007/7

Y1 - 2007/7

N2 - Objective: Selective serotonin reuptake inhibitors (SSRIs) are used to treat interferon-associated depression in patients receiving hepatitis C virus therapy. Prior studies have cautioned against the combined use of SSRIs and interferon due to increased risk of hemorrhage. Given the morbidity of depression and its impact on interferon compliance, we sought to reexamine the data. Method: In a retrospective analysis of our database of hepatitis C virus patients, a consecutive series of 303 patients (receiving treatment between January 2001 and January 2005) were evaluated for any evidence of bleeding. On the basis of our standard practice of care, patients were treated prophylactically with antidepressants for 3 to 4 weeks before beginning combination therapy with interferon and ribavirin. Patients were evaluated every 4 weeks during antiviral treatment with physical examinations and complete blood cell counts with differentials and platelets. Results: The overall rate of bleeding in our study was 0.3%, representing a single case of hemophilia. Conclusions: The bleeding risk of SSRIs is lower than previously reported.

AB - Objective: Selective serotonin reuptake inhibitors (SSRIs) are used to treat interferon-associated depression in patients receiving hepatitis C virus therapy. Prior studies have cautioned against the combined use of SSRIs and interferon due to increased risk of hemorrhage. Given the morbidity of depression and its impact on interferon compliance, we sought to reexamine the data. Method: In a retrospective analysis of our database of hepatitis C virus patients, a consecutive series of 303 patients (receiving treatment between January 2001 and January 2005) were evaluated for any evidence of bleeding. On the basis of our standard practice of care, patients were treated prophylactically with antidepressants for 3 to 4 weeks before beginning combination therapy with interferon and ribavirin. Patients were evaluated every 4 weeks during antiviral treatment with physical examinations and complete blood cell counts with differentials and platelets. Results: The overall rate of bleeding in our study was 0.3%, representing a single case of hemophilia. Conclusions: The bleeding risk of SSRIs is lower than previously reported.

UR - http://www.scopus.com/inward/record.url?scp=34548318673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548318673&partnerID=8YFLogxK

M3 - Article

VL - 68

SP - 1024

EP - 1026

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 7

ER -